PPP1R3F

Summary

PPP1R3F (protein phosphatase 1 regulatory subunit 3F, HGNC:14944) is a protein-coding gene on chromosome Xp11.23, encoding Protein phosphatase 1 regulatory subunit 3F (Q6ZSY5). Glycogen-targeting subunit for protein phosphatase 1 (PP1).

This gene encodes a protein that has been identified as one of several type-1 protein phosphatase (PP1) regulatory subunits. One or two of these subunits, together with the well-conserved catalytic subunit, can form the PP1 holoenzyme, where the regulatory subunit functions to regulate substrate specificity and/or targeting to a particular cellular compartment. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 89801 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodevelopmental disorder (Strong, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 161 total — 1 likely-pathogenic
• MANE Select transcript: NM_033215

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14944
Approved symbol	PPP1R3F
Name	protein phosphatase 1 regulatory subunit 3F
Location	Xp11.23
Locus type	gene with protein product
Status	Approved
Aliases	Hb2E
Ensembl gene	ENSG00000049769
Ensembl biotype	protein_coding
OMIM	301104
Entrez	89801

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 6 protein_coding, 1 nonsense_mediated_decay

ENST00000055335, ENST00000376188, ENST00000466508, ENST00000471261, ENST00000495799, ENST00000652102, ENST00000942558

RefSeq mRNA: 2 — MANE Select: NM_033215 NM_001184745, NM_033215

CCDS: CCDS35254, CCDS55415

Canonical transcript exons

ENST00000055335 — 4 exons

Exon	Start	End
ENSE00001409812	49269793	49270873
ENSE00001469646	49285834	49288090
ENSE00001469664	49281981	49282063
ENSE00003637153	49281406	49281461

Expression profiles

Bgee: expression breadth ubiquitous, 221 present calls, max score 94.91.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 2.6307 / max 29.7496, expressed in 1263 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
196330	1.2853	794
196331	1.0790	637
196332	0.2664	120

Top tissues by expression

247 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	94.91	gold quality
prefrontal cortex	UBERON:0000451	92.62	gold quality
right frontal lobe	UBERON:0002810	91.88	gold quality
anterior cingulate cortex	UBERON:0009835	91.51	gold quality
Brodmann (1909) area 9	UBERON:0013540	91.02	gold quality
frontal cortex	UBERON:0001870	90.61	gold quality
neocortex	UBERON:0001950	90.30	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	89.86	gold quality
right hemisphere of cerebellum	UBERON:0014890	89.86	gold quality
cerebellar hemisphere	UBERON:0002245	89.52	gold quality
cerebellar cortex	UBERON:0002129	89.47	gold quality
apex of heart	UBERON:0002098	89.40	gold quality
pons	UBERON:0000988	89.39	gold quality
cerebellum	UBERON:0002037	89.12	gold quality
amygdala	UBERON:0001876	89.00	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	88.84	gold quality
cerebral cortex	UBERON:0000956	88.80	gold quality
gastrocnemius	UBERON:0001388	88.64	gold quality
primary visual cortex	UBERON:0002436	88.46	gold quality
hypothalamus	UBERON:0001898	88.42	gold quality
Brodmann (1909) area 23	UBERON:0013554	88.35	gold quality
pancreatic ductal cell	CL:0002079	88.15	silver quality
spinal cord	UBERON:0002240	87.96	gold quality
muscle of leg	UBERON:0001383	87.80	gold quality
nucleus accumbens	UBERON:0001882	87.80	gold quality
brain	UBERON:0000955	87.58	gold quality
forebrain	UBERON:0001890	87.56	gold quality
middle temporal gyrus	UBERON:0002771	87.55	gold quality
upper arm skin	UBERON:0004263	87.38	silver quality
occipital lobe	UBERON:0002021	87.37	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.36

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

46 targeting PPP1R3F, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-130B-5P	99.83	68.50	1888
HSA-MIR-4530	99.69	66.47	1509
HSA-MIR-4328	99.57	71.06	4094
HSA-MIR-17-3P	99.55	66.77	1311
HSA-MIR-4687-3P	99.48	66.41	968
HSA-MIR-548B-3P	99.38	67.26	1000
HSA-MIR-520A-5P	99.35	66.72	1632
HSA-MIR-525-5P	99.35	66.85	1615
HSA-MIR-6830-5P	99.01	68.73	1884
HSA-MIR-6749-3P	99.00	65.73	1443
HSA-MIR-4297	98.77	66.95	2013
HSA-MIR-7113-3P	98.75	65.71	1120
HSA-MIR-330-5P	98.73	67.63	1788
HSA-MIR-214-3P	98.71	68.12	2128
HSA-MIR-326	98.25	66.44	1565
HSA-MIR-561-5P	98.25	68.13	1365
HSA-MIR-4768-3P	98.16	66.02	2330
HSA-MIR-211-3P	98.14	66.77	1052
HSA-MIR-4518	98.12	66.82	1030

Literature-anchored findings (GeneRIF, showing 3)

• Methylation of three genes encoded by X chromosome in blood leukocytes and colorectal cancer risk. (PMID:34145793)
• Hemizygous variants in protein phosphatase 1 regulatory subunit 3F (PPP1R3F) are associated with a neurodevelopmental disorder characterized by developmental delay, intellectual disability and autistic features. (PMID:37531237)
• Maps this gene as HB2E at the DXS9823E marker sequence. (PMID:8938429)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Ppp1r3f	ENSMUSG00000039556
rattus_norvegicus	Ppp1r3f	ENSRNOG00000068767
drosophila_melanogaster	Gbs-70E	FBGN0036428
caenorhabditis_elegans		WBGENE00019211

Paralogs (6): PPP1R3C (ENSG00000119938), PPP1R3D (ENSG00000132825), PPP1R3A (ENSG00000154415), PPP1R3B (ENSG00000173281), PPP1R3G (ENSG00000219607), PPP1R3E (ENSG00000235194)

Protein

Protein identifiers

Protein phosphatase 1 regulatory subunit 3F — Q6ZSY5 (reviewed: Q6ZSY5)

All UniProt accessions (3): A0A494C178, Q6ZSY5, H7C546

UniProt curated annotations — full annotation on UniProt →

Function. Glycogen-targeting subunit for protein phosphatase 1 (PP1).

Subcellular location. Membrane.

Tissue specificity. Expressed in brain, skeletal muscle and heart.

Isoforms (2)

UniProt ID	Names	Canonical?
Q6ZSY5-1	1	yes
Q6ZSY5-2	2

RefSeq proteins (2): NP_001171674, NP_149992* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005036	CBM21_dom	Domain
IPR038175	CBM21_dom_sf	Homologous_superfamily
IPR050782	PP1_regulatory_subunit_3	Family

Pfam: PF03370

UniProt features (27 total): modified residue 7, region of interest 6, compositionally biased region 3, topological domain 2, splice variant 2, sequence variant 2, chain 1, short sequence motif 1, transmembrane region 1, sequence conflict 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6ZSY5-F1	49.88	0.10

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (7): 14, 18, 420, 421, 547, 589, 594

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 111 (showing top): GOBP_POLYSACCHARIDE_BIOSYNTHETIC_PROCESS, GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_UP, GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY, HERNANDEZ_ABERRANT_MITOSIS_BY_DOCETACEL_2NM_DN, HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_2_DN, GOBP_GENERATION_OF_PRECURSOR_METABOLITES_AND_ENERGY, GOBP_REGULATION_OF_CARBOHYDRATE_METABOLIC_PROCESS, GOBP_CARBOHYDRATE_METABOLIC_PROCESS, GOBP_REGULATION_OF_GLYCOGEN_METABOLIC_PROCESS, GOBP_REGULATION_OF_CARBOHYDRATE_BIOSYNTHETIC_PROCESS, GOBP_REGULATION_OF_POLYSACCHARIDE_METABOLIC_PROCESS, CCCAGAG_MIR326, GOBP_REGULATION_OF_GENERATION_OF_PRECURSOR_METABOLITES_AND_ENERGY, GOCC_PROTEIN_PHOSPHATASE_TYPE_1_COMPLEX, ZHENG_BOUND_BY_FOXP3

GO Biological Process (2): regulation of glycogen biosynthetic process (GO:0005979), regulation of glycogen (starch) synthase activity (GO:2000465)

GO Molecular Function (4): protein phosphatase 1 binding (GO:0008157), protein phosphatase binding (GO:0019903), glycogen binding (GO:2001069), protein binding (GO:0005515)

GO Cellular Component (2): protein phosphatase type 1 complex (GO:0000164), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
glycogen biosynthetic process	1
regulation of glucan biosynthetic process	1
regulation of glycogen metabolic process	1
alpha-1,4-glucan glucosyltransferase (UDP-glucose donor) activity	1
regulation of transferase activity	1
protein phosphatase binding	1
phosphatase binding	1
polysaccharide binding	1
binding	1
cytoplasm	1
protein serine/threonine phosphatase complex	1
cellular anatomical structure	1

Protein interactions and networks

STRING

614 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PPP1R3F	GAGE10	A6NGK3	572
PPP1R3F	NBDY	A0A0U1RRE5	514
PPP1R3F	PPP1R3E	Q9H7J1	433
PPP1R3F	GAGE12H	A6NDE8	419
PPP1R3F	WDR13	Q9H1Z4	404
PPP1R3F	ACBD4	Q8NC06	385
PPP1R3F	PPP1R3A	Q16821	381
PPP1R3F	FAM156A	Q8NDB6	369
PPP1R3F	PPP1R3B	Q86XI6	322
PPP1R3F	ZNF697	Q5TEC3	306
PPP1R3F	LGALS16	A8MUM7	300
PPP1R3F	SPACA5B	Q96QH8	300
PPP1R3F	ZNF182	P17025	291
PPP1R3F	ACBD5	Q5T8D3	291
PPP1R3F	EFHC2	Q5JST6	290

IntAct

20 interactions, top by confidence:

A	B	Type	Score
WDR5	KMT2D	psi-mi:“MI:0914”(association)	0.910
PPP1CC	CCDC85C	psi-mi:“MI:0914”(association)	0.740
WDR5	MEN1	psi-mi:“MI:0914”(association)	0.710
GYG2	GYS1	psi-mi:“MI:0914”(association)	0.660
DYRK1B	BMAL1	psi-mi:“MI:0914”(association)	0.530
PPP1R3F	AGTR1	psi-mi:“MI:0915”(physical association)	0.370
PPP1R3F	GPR35	psi-mi:“MI:0915”(physical association)	0.370
PPP1R3F	HTR2B	psi-mi:“MI:0915”(physical association)	0.370
PPP1R3F	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
PPP1CC	CCDC85C	psi-mi:“MI:0914”(association)	0.350
WDR5	KDM6A	psi-mi:“MI:0914”(association)	0.350
DYRK1B	POM121C	psi-mi:“MI:0914”(association)	0.350
TLK2	IGKV1D-13	psi-mi:“MI:0914”(association)	0.350
CHD8	IGLV4-60	psi-mi:“MI:0914”(association)	0.350
DYRK1A	TEX13D	psi-mi:“MI:0914”(association)	0.350
ITM2B	ILVBL	psi-mi:“MI:0914”(association)	0.350
PYGB	GYG2	psi-mi:“MI:0914”(association)	0.350
DYRK1A	SIPA1L1	psi-mi:“MI:0914”(association)	0.350

BioGRID (27): PPP1R3F (Affinity Capture-MS), PPP1R3F (Affinity Capture-MS), PPP1R3F (Affinity Capture-MS), PPP1R3F (Affinity Capture-MS), PPP1R3F (Affinity Capture-MS), PPP1R3F (Affinity Capture-MS), PPP1R3F (Proximity Label-MS), PPP1R3F (Proximity Label-MS), PPP1R3F (Two-hybrid), PPP1R3F (Two-hybrid), PPP1R3F (Two-hybrid), PPP1R3F (Two-hybrid), PPP1R3F (Reconstituted Complex), PPP1R3F (Affinity Capture-RNA), PPP1R3F (Affinity Capture-MS)

ESM2 similar proteins: A2VE02, A4D1S0, A6NEL2, B2RU40, C9JH25, D4A9R4, E7EW31, O43593, O94850, O95196, O95873, P0DPE3, P60669, Q1HCM0, Q2M3G4, Q3UPH7, Q5BK39, Q5FWE3, Q5JPB2, Q5M844, Q5RCQ2, Q5U2P6, Q5VZ46, Q5XJV6, Q64322, Q6P1B3, Q6PE13, Q6UWD8, Q6ZSY5, Q76NI1, Q7Z591, Q8BZW2, Q8C708, Q8IWN7, Q8IYJ0, Q8NAV2, Q8NC74, Q8TER5, Q924A2, Q95K74

Diamond homologs: B7ZBB8, O95685, P0C7L8, Q00756, Q6DDQ5, Q6GL23, Q6IN01, Q6ZSY5, Q7TMB3, Q86XI6, Q8BRJ4, Q8C767, Q99MR9, Q9CW07, Q9H7J1, Q9JIG4, Q9VVY3, A6QNP3, Q16821, Q28E28, Q5BL87, Q6GQ68, Q6P950, Q803M0, Q9UQK1, T1SFR8, Q0VCR4, P40036, Q5U2R5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

161 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	121
Likely benign	21
Benign	3

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
4686600	NM_033215.5(PPP1R3F):c.1257dup (p.Ser420fs)	Likely pathogenic

SpliceAI

727 predictions. Top by Δscore:

Variant	Effect	Δscore
X:49281400:CTGCA:C	acceptor_loss	1.0000
X:49281401:TGCAG:T	acceptor_loss	1.0000
X:49281402:GCAGG:G	acceptor_loss	1.0000
X:49281403:CAG:C	acceptor_loss	1.0000
X:49281404:A:AG	acceptor_gain	1.0000
X:49281404:A:G	acceptor_loss	1.0000
X:49281405:G:GG	acceptor_gain	1.0000
X:49281405:GGCCT:G	acceptor_gain	1.0000
X:49281460:GG:G	donor_gain	1.0000
X:49281461:GG:G	donor_gain	1.0000
X:49281462:G:GG	donor_gain	1.0000
X:49281980:GCA:G	acceptor_gain	1.0000
X:49281980:GCAGA:G	acceptor_gain	1.0000
X:49277331:GCC:G	donor_gain	0.9900
X:49281396:T:A	acceptor_gain	0.9900
X:49281404:AG:A	acceptor_gain	0.9900
X:49281405:GG:G	acceptor_gain	0.9900
X:49281405:GGC:G	acceptor_gain	0.9900
X:49281405:GGCC:G	acceptor_gain	0.9900
X:49281457:CATGG:C	donor_gain	0.9900
X:49281458:ATGG:A	donor_gain	0.9900
X:49281459:TGG:T	donor_gain	0.9900
X:49281460:GGG:G	donor_gain	0.9900
X:49281975:CTCTA:C	acceptor_loss	0.9900
X:49281976:TCTAG:T	acceptor_loss	0.9900
X:49281977:CTAG:C	acceptor_loss	0.9900
X:49281978:TA:T	acceptor_loss	0.9900
X:49281979:A:AG	acceptor_gain	0.9900
X:49281979:AG:A	acceptor_loss	0.9900
X:49281980:G:GA	acceptor_gain	0.9900

AlphaMissense

5090 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:49270651:T:C	F261S	0.999
X:49270717:T:A	V283D	0.998
X:49270596:T:C	F243L	0.997
X:49270597:T:C	F243S	0.997
X:49270598:T:A	F243L	0.997
X:49270598:T:G	F243L	0.997
X:49270603:T:C	F245S	0.997
X:49286348:T:G	I553S	0.997
X:49270433:G:C	W188C	0.996
X:49270433:G:T	W188C	0.996
X:49286164:T:G	Y492D	0.996
X:49286348:T:C	I553T	0.996
X:49270431:T:A	W188R	0.995
X:49270431:T:C	W188R	0.995
X:49270662:T:G	Y265D	0.995
X:49286153:T:C	L488P	0.995
X:49286177:T:C	L496P	0.995
X:49270392:T:C	F175L	0.994
X:49270394:C:A	F175L	0.994
X:49270394:C:G	F175L	0.994
X:49270602:T:C	F245L	0.994
X:49270604:C:A	F245L	0.994
X:49270604:C:G	F245L	0.994
X:49270660:G:C	R264P	0.994
X:49270683:T:C	F272L	0.994
X:49270685:C:A	F272L	0.994
X:49270685:C:G	F272L	0.994
X:49270686:T:A	W273R	0.994
X:49270686:T:C	W273R	0.994
X:49270688:G:C	W273C	0.994

dbSNP variants (sampled 300 via entrez): RS1000512240 (X:49279876 C>A), RS1000584959 (X:49288739 G>A,T), RS1000851017 (X:49296169 T>G), RS1001002971 (X:49272154 T>C), RS1001069848 (X:49271850 G>A), RS1001196081 (X:49299262 C>A,T), RS1001334784 (X:49273926 G>A), RS1002203737 (X:49291294 C>A,G,T), RS1002588247 (X:49292692 G>C), RS1003044144 (X:49275555 T>G), RS1003148674 (X:49284006 T>A), RS1003169868 (X:49269326 C>T), RS1003350446 (X:49277423 C>G), RS1003381497 (X:49277203 T>C), RS1004229729 (X:49285687 A>G)

Disease associations

OMIM: gene MIM:301104 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
neurodevelopmental disorder	Strong	X-linked

Mondo (1): neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST007798_116	Asthma	7.000000e-11
GCST007800_88	Asthma (childhood onset)	6.000000e-10

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

17 total (human), top 17 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	increases expression	1
sodium arsenite	increases expression	1
abrine	increases expression	1
bisphenol S	affects cotreatment, decreases expression	1
jinfukang	decreases expression, affects cotreatment	1
Acetaminophen	increases expression	1
Benzo(a)pyrene	affects methylation	1
Cisplatin	decreases expression, affects cotreatment	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Dexamethasone	affects cotreatment, decreases expression	1
Drugs, Chinese Herbal	increases expression	1
Indomethacin	affects cotreatment, decreases expression	1
Naphthoquinones	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Valproic Acid	increases methylation	1
1-Methyl-3-isobutylxanthine	affects cotreatment, decreases expression	1
Acrylamide	increases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TF84	HAP1 PPP1R3F (-) 1	Cancer cell line	Male
CVCL_TF85	HAP1 PPP1R3F (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice